Related references
Note: Only part of the references are listed.The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma
J. R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Effect of alternative temozolomide schedules on glioblastoma O6-methylguanine-DNA methyltransferase activity and survival
C. G. Robinson et al.
BRITISH JOURNAL OF CANCER (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
Stephen Yip et al.
CLINICAL CANCER RESEARCH (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas
Casilda Balmaceda et al.
CANCER (2008)
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma
Ilse Vlassenbroeck et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
Daniel P. Cahill et al.
CLINICAL CANCER RESEARCH (2007)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
A. A. Brandes et al.
BRITISH JOURNAL OF CANCER (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
AW Tolcher et al.
BRITISH JOURNAL OF CANCER (2003)
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
M Esteller
ONCOGENE (2002)
Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen
P Taverna et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
